

MPN&MPNr-EuroNet

Ex-COST Action BM0902 (2009-2013)

Description of MPN&MPNr-EuroNet

Philadelphia-negative myeloproliferative neoplasms (MPNs) are rare clonal diseases characterized by chronic elevation of blood cell counts (red blood cells, platelets, granulocytes), splenomegaly, and fibrosis of the bone marrow. There are three MPNs: polycythemia vera (PV), characterized by over production of red blood cells; essential thrombocythemia (ET), characterized by overproduction of platelets; and primary myelofibrosis (PMF), characterized by splenomegaly and fibrosis of the bone marrow.

In 2005, the discovery in Europe of the V617F mutation in the *JAK2* gene in the majority of MPNs has renewed interest in these diseases.¹ Since 2005, mutations in two other genes, *MPL* (2006) and *CALR* (2013), have been discovered in MPNs with no *JAK2V617F* mutation.^{2,3} Consequently, new diagnostic tools have been designed to detect and quantify the *JAK2V617F* mutation, as well as the *MPLW515L/K* and *CALR* mutations characteristic of MPNs. In addition, several other genes have been described as mutated in MPNs, as well as in other hematological malignancies; some of the additional mutations may serve as prognostic markers. Similar progress has been made in the rare congenital/hereditary diseases related to MPNs (MPNr), such as congenital erythrocytosis (CE) and hereditary thrombocytosis (HT). Several genes have been described as abnormal in these diseases but the diagnosis of patients remain difficult and too often, not done.

In 2007, a group of European biologists decided to share their expertise in the new molecular assays designed to detect the mutations identified in MPNs and in MPN-related diseases. This informal network led to the first international comparative study of *JAK2V617F* assays, in an effort to harmonize the detection and improve the quantification of the main MPN mutation.⁴ The new European network was made official as MPN&MPNr-EuroNet in November 2009 thanks to the creation of COST Action BM0902, funded by the Co-Operation in Science and Technology (COST) programme, until November 2013.

MPN&MPNr-EuroNet, now strong of 155 members representing 32 countries, fosters cooperation among European MPN experts to improve understanding of MPNs and related hereditary diseases and to facilitate and harmonize the diagnosis of these diseases in Europe. Each spring, MPN&MPNr-EuroNet organizes an international meeting, open to all. Since 2014, the network has been supported by the MPN&MPNr-EuroNet Fund, within the Project Foundation of the Université of Nantes, France.

References

1. James C et al. A unique clonal *JAK2* mutation leading to constitutive signalling causes polycythaemia vera. **Nature** 2005; 434: 1144-8.
2. Pikman Y et al. *MPLW515L* is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. **PLoS Med** 2006; 3 :e270.
3. Klampfl T et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. **N Engl J Med** 2013; 369: 2379-90.
4. Jovanovic JV et al. Establishing Optimal Quantitative-Polymerase Chain Reaction Assays for Routine Diagnosis and Tracking Minimal Residual Disease in *JAK2V617F* Associated Myeloid Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet (COST Action BM0902) Study. **Leukemia** 2013; 27(10):2032-2039.

Main Achievements of MPN&MPNr-EuroNet

Since 2009 MPN&MPNr-EuroNet has optimized *JAK2V617F* assays and determined reference *JAK2V617F* standards. During the 2009-2013 period, joint collaborative studies between MPN&MPNr-EuroNet and European Leukemia Net led to the determination of the optimal *JAK2V617F* assays recommended for diagnostic use in Europe (Jovanovic *et al.*, 2013). These studies indicated a strong need for reference materials to enable standardization of *JAK2V617F* testing and quantification (Lippert *et al.*, 2009; Asp *et al.*, 2017). More recently, MPN&MPNr-EuroNet collaborated with the National Institute of Biological Standards and Controls (NIBSC, UK) to produce a panel of genomic *JAK2V617F*-mutated reference DNAs, which was approved in October 2016 by the World Health Organization (WHO) as the 1st WHO International Genomic Reference Panel for *JAK2V617F*, for both mutation detection and quantification. Regarding CE and HT, MPN&MPNr-EuroNet has centralized and organized the detection of the main CE- and HT- associated mutations, notably by using Next Generation sequencing (NGS). MPN&MPNr-EuroNet has also helped diffuse information about these very rare diseases, including via publications and reviews (Hussein *et al.*, 2014; Bento *et al.*, 2014). Thanks to the COST program, in 2014 a book dedicated to CE and HT has been published. Altogether, MPN&MPNr-EuroNet has published 22 articles or reviews (listed below). Finally, since 2009, MPN&MPNr-EuroNet has helped communication and scientific exchanges between researchers, biologists and clinicians via the organization of 14 international meetings dedicated to MPNs, CE and HT.

Publications of MPN&MPNr-EuroNet (2009-2019)

1. Lippert E et al. Concordance of assays designed for the quantitation of *JAK2V617F* (1849G>T): a multi-centre study. **Haematologica** 2009; 94: 38-45.
2. www.nibsc.org/science_and_research/advanced_therapies/genomic_reference_materials/jak2_v617f
3. Cario H et al. Erythrocytosis in children and adolescents -classification, characterization, and consensus recommendations for the diagnostic approach. **Pediatr Blood Cancer** 2013; 60:1734-38.
4. Hussein K et al. Clinical utility gene card for: Hereditary thrombocytosis. **Eur J Human Genet** 2014; 22(2). doi: 10.1038/ejhg.2013.117.Jun 5.
5. Bento C et al.; on behalf of ECE-Consortium. Genetic basis of Congenital Erythrocytosis: mutation update and online databases. **Human Mutation** 2014; 35:15-26. doi: 10.1002/humu.22448.
6. Gardie B et al. The role of PHD2 mutations in the pathogenesis of erythrocytosis. **Hypoxia** 2014; 2:71-90. eCollection 2014. Review.
7. Gross M et al. Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by EGF receptor-EPOR chimeras. **Br J Haematol** 2014 ; 165(4):519-28.
8. Bento C et al., on behalf of COST Action BM0902 (MPN&MPNr-EuroNet). **Congenital Erythrocytosis & Hereditary Thrombocytosis** (Book), 2014.
9. Lippert E et al. Clinical and biological characterization of patients with low (0.1-2%) *JAK2V617F* allele burden at diagnosis. **Haematologica** 2014; 99 (7): e098-101.
10. Barosi G et al. Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from ELN and IWG-MRT. **Leukemia** 2015; 29(1):20-6. doi: 10.1038/leu.2014.250. Review.
11. Langabeer SE et al., on behalf of the MPN&MPNr-EuroNet. Molecular diagnostics of myeloproliferative neoplasms (MPN). **Eur J Hematol** 2015;95(4):270-9. doi: 10.1111/ejh.12578.
12. Hermouet S, Hasselbalch HC, Cokic V. Mediators of inflammation in myeloproliferative neoplasms: State of the Art. **Mediators Inflamm** 2015; 964613. doi: 10.1155/2015/964613. Editorial.

13. Hermouet S et al. Pathogenesis of myeloproliferative neoplasms: Role and mechanisms of chronic inflammation. **Mediators Inflamm** 2015; 145293. doi: 10.1155/2015/145293. Review.
14. McMullin MF et al. Outcomes of pregnancy in patients with congenital erythrocytosis. **Br J Haematol** 2015;170(4):586-588.
15. McMullin MF, Cario H. LNK mutations and myeloproliferative disorders. **Am J Hematol** 2016; 91(2):248-251. Review.
16. Panovska-Stavridis I et al. Essential Thrombocythemia associated with germline JAK2 G571S variant and somatic CALR type 1 mutation. **Clin Lymphoma Myeloma Leuk** 2016; 16(5):e55-7.
17. Bento C et al. Primary Familial and Congenital Polycythemia. Gene Reviews. 2016. University of Washington, Seattle.
18. Biagetti G et al. HFE mutations in idiopathic erythrocytosis. **Haematologica** 2016; 101:1306-1318.
19. Camps C et al. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. **Br J Haematology** 2017; Feb 7 PMID: 28169423
20. Cleyrat C et al. Gene Editing rescue of a novel *MPL* mutant associated with congenital amegakaryocytic thrombocytopenia. **Blood Advances** 2017; 1:1815-1826.
21. Catherwood MA et al. Absence of *CALR* mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. **Acta Haematologica** 2018; 139(4):217-219. doi: 10.1159/000489006.
22. Asp J et al. International quality assurance of *JAK2V617F* quantification. **Annals Hematol** 2019; 98(5):1111-1118. doi: 10.1007/s00277-018-3570-8.